DescriptionGene therapies are being developed which seek to repair the spinal cord and give patients back their mobility by lentivirus-mediated expression of neurogenic transcription factors. Through targeted overexpression of key transcription factors, endogenous cells can be motivated to remodel the site of injury. Previously, our lab has identified a gene therapy in a mouse model of hemisection spinal cord injury (SCI) that, when injected immediately after injury, produces locomotor functional recovery by decreasing cell death, promoting proliferation, and activating neural stem cells. However, in clinical settings, therapeutic intervention would happen hours or even days after the injury. Thus, we aim to determine the effect of a delayed treatment for effective gene therapies of spinal cord injuries. Our hypothesis is that injecting the therapeutic agent some time after injury will still be effective to promote functional recovery. In this study, we used a lateral hemisection SCI mouse model and injected the lentiviral gene therapy one day after injury. The spinal cord tissue was harvested, stained, and analyzed at three different timepoints after the injection to determine the effects of the therapy on the site of injury. Our results showed successful overexpression of the target transcription factor and consequently, decreased cell death in the subacute phase of injury, increased neural stem cell activation, and an increase in cholinergic neurons around the injury site. Our results show that the therapy successfully remodeled the site of injury and could potentially lead to functional recovery in a long-term study. Improving the SCI mouse model for testing gene therapies will better predict their efficacy in clinical settings.